pretickt

Twist Bioscience TWST stock

Twist Bioscience Corporation · Healthcare · end-of-day data as of Nov 13, 2026

Twist Bioscience
TWST · $7.35B
$111.60-2.3%
Nov 13, 2026 · close
$150$200SepOctNov9:3016:003 months -3.9%Nov 13close
▲ Bullish readings 3
  • Price target at$145.70 +30.6%
  • ConsensusBuy · 13
  • Sector▲ +15.9%
Neutral
  • Earnings in80d
  • RSI38
  • Support-50.2%
  • Resistance+55.4%
  • Off 52w high-49.2%
  • Volume0.8x
  • Bollingerlower half
  • News1.00
  • Trendsideways
  • 52w range$23–$220
  • ATR+15.1%
  • Off ATH-49.2%
▼ Bearish readings 4
  • Insiders-$99.86M
  • MAs1 of 4
  • MA20×50Death 9d ago
  • MACD-3.21

Updates with the 15-min delayed price; analysts, insiders and news are from the last close. Not a forecast or investment advice.

The average 12-month analyst price target for Twist Bioscience TWST is $145.70, 30.6% above the last close of $111.60 on Nov 13, 2026; targets range from $89.00 to $215.00. Rating consensus: Buy.

What changed

Twist Bioscience TWST · Nov 13, 2026

Twist Bioscience fell 2.3% on Nov 13 as healthcare stocks rose

It had dropped 6.8% on Nov 12, the day of its report, and Canaccord Genuity set a $150.00 target on Nov 13.

  • Last close (Nov 13): TWST -2.3% = market (SPY) -0.4% + Healthcare sector +0.7% + TWST on its own -2.7%.
  • Twist Bioscience reported EPS of -$0.32 against -$0.39 expected on Nov 12, 2026 before the open; the stock moved -6.8% that session.
  • Price targets published on Nov 13: Canaccord Genuity $150.00.

Wording by an AI model from pretickt's data; the dated facts under it are the platform's own. Not investment advice.

Analyst price targets and predictions

10 firms with a target in the last 12 months · last close $111.60 · as of Nov 13, 2026

— actual price● bullish target● bearish target┄ last close, high, average and low targethover a dot to see the analysts behind it ·wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets
⇔⇕$215HIGH$146AVERAGE$112TODAY$89.00LOWNov 25Apr 26Sep 26Feb 27Jul 27Dec 27-64%-55%-45%-19%+2%+36%+84%+23%
13

Strong buy 2Buy 7Hold 3Sell 1Strong sell 0

13 analysts in November 2026: 9 rate it a buy or strong buy (69%), 3 a hold and 1 a sell or strong sell. A year earlier, 89% rated it a buy or strong buy.

Is Twist Bioscience a good stock to buy?

Twist Bioscience is strong on 2 of the 5 questions about the business; weak on advantage, economics and execution. With a loss over the last 12 months, Twist Bioscience has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage easy to copy
  3. Economics losing money
  4. Execution misses
  5. Fragility sturdy
  6. Price like its peers
TWST: the 6 questions, card by card

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.

Snapshot

  • P/E—
  • P/E vs sector—
  • P/E vs own—
  • Price target at+30.6%
  • ConsensusBuy
  • Market cap$7.35B
  • FCF yield—
  • Insiders-$99.86M
  • Earnings in80d
  • News1.00

Why it moved

Twist Bioscience TWST fell 2.3% on Nov 13, 2026.

The market (SPY) fell 0.4%; Healthcare stocks rose 0.4%. Most of the move is specific to Twist Bioscience TWST.

Market (SPY)-0.4%
Healthcare sector+0.7%
TWST specific-2.7%

1 story on the day (30-day average 0.8).

Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.

Price and events

⇔⇕$37.12$89.19$141$193Nov 25Feb 26May 26Aug 26Nov 26Feb 27EEEAAEEE

Last close $111.60 · +273.2% over 1y · E earnings · D dividend · S split · A analyst rating change

Technicals

Twist Bioscience TWST closed at $111.60 on Nov 13, 2026, 19.7% above its 200-day moving average of $93.24 and 25.7% below its 50-day moving average of $150.23. It is 49.2% below its 52-week high of $219.71; its 52-week low is $23.30.

  • Trendsideways
  • Sector▲ +15.9%
  • MAs20▼ 50▼ 100▼ 200▲
  • Above MAs1 of 4 above
  • MA20×50Death 9d ago
  • RSI38
  • Support-50.2%
  • Resistance+55.4%
  • Off 52w high-49.2%
  • Off ATH-49.2%
  • 52w range$111.60
  • Bollingerlower half
  • MACD-3.21
  • ATR+15.1%
  • Volume0.8x

Revenue and free cash flow

Q4 FY2026: Revenue +27.9% year over year, operating margin -25.0%.

RevenueFree cash flow
Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026
Q4 FY2026Sep 30, 2026$127M-0.31—53.1%-25.0%-16.3%
Q3 FY2026Jun 30, 2026$118M-0.56-$8.55M52.8%-30.6%-29.6%
Q2 FY2026Mar 31, 2026$111M-0.71-$25.55M51.6%-34.9%-39.8%
Q1 FY2026Dec 31, 2025$104M-0.50-$34.79M52.0%-31.7%-29.4%
Q4 FY2025Sep 30, 2025$99.01M-0.45-$24.24M51.3%-30.2%-27.4%
Q3 FY2025Jun 30, 2025$96.06M0.33-$10.56M53.4%-31.4%21.2%
Q2 FY2025Mar 31, 2025$92.79M-0.66-$17.13M49.6%-44.8%-42.4%
Q1 FY2025Dec 31, 2024$88.71M-0.53-$23.7M48.3%-39.1%-35.6%

Peers

20D
1VRTXVertex$538.60-0.7%-5.3%+6.6%34.7$137B
2REGNRegeneron$955.47+0.4%-3.7%-6.4%21.1$98.82B
3MRNAModerna$223.37-3.4%-20.5%-45.2%—$90.38B
4INCYIncyte$120.97-0.6%-8.8%+9.8%64.3$24.66B
5ALNYAlnylam$165.04+5.4%-65.6%+113.7%8.3$22.11B
6TECHBio-Techne$72.80+0.1%-0.1%-7.7%66.2$11.44B
7TWSTTwist Bioscience$111.60-2.3%-49.2%+30.6%—$7.35B
8CRSPCRISPR Therapeutics$42.24-0.9%-33.4%+71.5%—$4.1B

Data as of Nov 13, 2026 close.

Latest news

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.